Related Experiment Video

Updated: Mar 26, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
07:46

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

26.1K

Dynamics of circulating microparticles in obesity after weight loss

Elena Campello1, Eva Zabeo2, Claudia M Radu2

  • 1Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine (DIMED), University of Padua, Via Ospedale Civile 105, 35100, Padua, Italy. elena.campello83@gmail.com.

Internal and Emergency Medicine
|February 4, 2016
PubMed

Insights

Weight loss through bariatric surgery significantly reduces microparticle (MP) levels in obese patients. These reductions correlate with decreased BMI, leptin, and inflammation markers, suggesting improved cardiovascular health.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Research
  • Obesity Medicine

Background:

  • The relationship between obesity and microparticle (MP) production remains unclear.
  • Microparticles are implicated in various physiological and pathological processes, including inflammation and coagulation.
  • Obesity is a significant risk factor for cardiovascular disease, often associated with a pro-inflammatory and pro-thrombotic state.

Purpose of the Study:

  • To prospectively evaluate the impact of weight loss on circulating microparticle (MP) levels in patients with severe obesity.
  • To investigate the correlation between changes in MP subtypes and reductions in BMI, leptin, and hs-CRP following bariatric surgery.

Main Methods:

  • Prospective study of 20 patients with Class III obesity (BMI ≥ 40 kg/m²).
  • Measurement of plasma MP subtypes (annexin V-MP, endothelial-derived MP, platelet-derived MP, leukocyte-derived MP, TF+ MP, CD36+ MP) at baseline (T0), 3 months (T3), and 12 months (T12) after sleeve gastrectomy (SLG).
  • Assessment of body weight, BMI, leptin, and hs-CRP levels at the same time points.

Main Results:

  • Significant reductions in most MP subtypes (except endothelial-derived MP) were observed by 12 months post-SLG, coinciding with substantial weight loss (41%).
  • Reductions in leukocyte-derived, TF+ MP, and CD36+ MP were significantly correlated with reductions in leptin.
  • Reductions in leukocyte-derived and CD36+ MP were also significantly correlated with decreased hs-CRP levels, indicating reduced inflammation.

Conclusions:

  • Weight loss achieved through sleeve gastrectomy in morbidly obese patients leads to a significant decrease in circulating microparticles of various origins.
  • The reduction in MP levels is strongly associated with decreased BMI, leptin, and inflammatory markers, suggesting an improvement in the pro-thrombotic and inflammatory state.
  • A potential trend of increasing MP levels 12 months post-surgery, excluding endothelial MPs, may indicate a slow, low-grade inflammatory state linked to adipose tissue prior to potential weight regain.
Keywords:
HypercoagulabilityInflammationMicroparticlesObesityTissue factor

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K
A Microphysiologic Platform for Human Fat: Sandwiched White Adipose Tissue08:14

A Microphysiologic Platform for Human Fat: Sandwiched White Adipose Tissue

Published on: August 15, 2018

6.8K

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
368
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
279
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
335
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K